Kael-GenVax successfully deployed the world’s first therapeutic vaccine for pancreatic cancer
The world’s first therapeutic vaccine for pancreatic cancer received approval for sales in Korea after passing the European clinical test
On September 15, the Ministry of Foods and Drug Safety (MFDS) announced to approve the new drug for pancreatic cancer treatment, Liavax Inj (Code GV1001), whi...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
